Rapid initiation of quetiapine well tolerated as compared with the conventional initiation regimen in patients with schizophrenia or schizoaffective disorders

Hsiao, Chih‐Cheng; Chen, Kun-Po; Tsai, Chang-Jer; Wang, Liang‐Jen; Chen, Chih-Ken; Lin, Shih‐Ku

doi:10.1016/j.kjms.2011.06.014

Cited by 8 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…QTF has antidepressant properties, which are likely to be mediated in part by its metabolite N-des alkyl quetiapine fumarate, which inhibits selective norepinephrine reuptake and activates the 5-HT1A and 5-HT7 receptors [3]. QTF also has a favorable safety record, as evidenced by numerous past clinical trials [4]. Many people with schizophrenia have stated that QTF enhances their cognitive abilities, and it is particularly well-tolerated in the elderly [5].…”

Section: Introductionmentioning

confidence: 99%

Brain Targeting of Quetiapine Fumarate via Intranasal Delivery of Loaded Lipospheres: Fabrication, In-Vitro Evaluation, Optimization, and In-Vivo Assessment

et al. 2022

View full text Add to dashboard Cite

A liposphere system for intranasal delivery of quetiapine fumarate (QTF) was created to assess the potential for enhanced drug delivery. We investigated the effects of particle size, entrapment effectiveness, poly dispersibility index, and pluronic incorporation percentage on these variables. The optimal formula was examined using a TEM, and investigations into DSC, XRD, and FTIR were made. Optimized liposphere formulation in vitro dissolution investigation with a mean diameter of 294.4 ± 18.2 nm revealed about 80% drug release in 6 h. The intranasal injection of QTF-loaded lipospheres showed a shorter Tmax compared to that of intranasal and oral suspension, per the findings of an in vivo tissue distribution investigation in Wistar mice. Lipospheres were able to achieve higher drug transport efficiency (DTE %) and direct nose-to-brain drug transfer (DTP %). A potentially effective method for delivering QTF to specific brain regions is the liposphere system.

show abstract

Section: Introductionmentioning

confidence: 99%

Brain Targeting of Quetiapine Fumarate via Intranasal Delivery of Loaded Lipospheres: Fabrication, In-Vitro Evaluation, Optimization, and In-Vivo Assessment

et al. 2022

View full text Add to dashboard Cite

show abstract

Antipsychotic dose reduction compared to dose continuation for people with schizophrenia

Rodolico

Siafis

Bighelli

et al. 2022

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Antipsychotic drugs are the mainstay treatment for schizophrenia, yet they are associated with diverse and potentially dose‐related side effects which can reduce quality of life. For this reason, the lowest possible doses of antipsychotics are generally recommended, but higher doses are often used in clinical practice. It is still unclear if and how antipsychotic doses could be reduced safely in order to minimise the adverse‐effect burden without increasing the risk of relapse. Objectives To assess the efficacy and safety of reducing antipsychotic dose compared to continuing the current dose for people with schizophrenia. Search methods We conducted a systematic search on 10 February 2021 at the Cochrane Schizophrenia Group's Study‐Based Register of Trials, which is based on CENTRAL, MEDLINE, Embase, CINAHL, PsycINFO, PubMed, ClinicalTrials.gov, ISRCTN, and WHO ICTRP. We also inspected the reference lists of included studies and previous reviews. Selection criteria We included randomised controlled trials (RCTs) comparing any dose reduction against continuation in people with schizophrenia or related disorders who were stabilised on their current antipsychotic treatment. Data collection and analysis At least two review authors independently screened relevant records for inclusion, extracted data from eligible studies, and assessed the risk of bias using RoB 2. We contacted study authors for missing data and additional information. Our primary outcomes were clinically important change in quality of life, rehospitalisations and dropouts due to adverse effects; key secondary outcomes were clinically important change in functioning, relapse, dropouts for any reason, and at least one adverse effect. We also examined scales measuring symptoms, quality of life, and functioning as well as a comprehensive list of specific adverse effects. We pooled outcomes at the endpoint preferably closest to one year. We evaluated the certainty of the evidence using the GRADE approach. Main results We included 25 RCTs, of which 22 studies provided data with 2635 participants (average age 38.4 years old). The median study sample size was 60 participants (ranging from 18 to 466 participants) and length was 37 weeks (ranging from 12 weeks to 2 years). There were variations in the dose reduction strategies in terms of speed of reduction (i.e. gradual in about half of the studies (within 2 to 16 weeks) and abrupt in the other half), and in terms of degree of reduction (i.e. median planned reduction of 66% of the dose up to complete withdrawal in three studies). We assessed risk of bias across outcomes predominantly as some concerns or high risk. No study reported data on the number of participants with a clinically important change in quality of life or functioning, and only eight studies reported continuous data on scales measuring quali...

show abstract

Quetiapine causing severe fall and skull fracture—A case report

Tay

2017

Asian Journal of Psychiatry

View full text Add to dashboard Cite

Rapid initiation of quetiapine well tolerated as compared with the conventional initiation regimen in patients with schizophrenia or schizoaffective disorders

Cited by 8 publications

References 19 publications

Brain Targeting of Quetiapine Fumarate via Intranasal Delivery of Loaded Lipospheres: Fabrication, In-Vitro Evaluation, Optimization, and In-Vivo Assessment

Brain Targeting of Quetiapine Fumarate via Intranasal Delivery of Loaded Lipospheres: Fabrication, In-Vitro Evaluation, Optimization, and In-Vivo Assessment

Antipsychotic dose reduction compared to dose continuation for people with schizophrenia

Quetiapine causing severe fall and skull fracture—A case report

Contact Info

Product

Resources

About